Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
116results about How to "Prevention and therapy" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Device and method for intra-bronchial provision of a therapeutic agent
InactiveUS6929637B2Inhibit movementLimit transportBronchiPharmaceutical delivery mechanismDuring expirationExhalation
The present invention includes an intra-bronchial device, system, and method for providing a therapeutic agent to a patient. A device includes a flow control member for placement in an air passageway communicating with a lung portion, and when deployed in the air passageway inhibits a therapeutic agent distal of the control member from moving proximal of the control member, and includes the therapeutic agent associated with the flow control member. The control member may inhibit movement of the therapeutic agent by limiting airflow, and may include a one-way valve limiting exhalation of air from the lung portion. The control member may include a flexible membrane impervious to air flow, or a separator arranged to inhibit the movement of the therapeutic agent. The control member may include at least one anchor, and the anchor may be releasable from the air passageway for removal of the intra-bronchial device.
Owner:GYRUS ACMI INC (D B A OLYMPUS SURGICAL TECH AMERICA)
Cardiac arrhythmia detector using ECG waveform-factor and its irregularity
InactiveUS6480734B1Avoiding unnecessary shockSignificant energy savingElectrocardiographyHeart defibrillatorsVentricular tachycardiaCardiac monitoring
A cardiac monitor is provided that monitors the condition of the heart of a cardiac patient and generates signals indicating one of several conditions, such as supraventricular tachycardia, ventricular tachycardia and ventricular fibrillation. In order to generate these signals, the ECG from the patient is analyzed to determine a cardiac interval and heart rate, as well as a waveform factor and a waveform factor irregularity. The waveform factor is derived from the average of the ECG amplitudes during a cardiac interval and the peak value of the ECG during the same interval. Preferably, a running average is calculated over several intervals. This waveform factor is then used to detect shockable ventricular arrhythmia. The waveform factor irregularity is indicative of the variability of the waveform factor and is used to differentiate between ventricular tachycardia and ventricular defibrillation.
Owner:ZOLL MEDICAL CORPORATION
Medical device for vessel compatibility during high pressure infusion
The invention provides devices that can be used to deliver a therapeutic agent to a treatment site within the vessel of a patient at increased pressure, while limiting the contact with and pressure placed on the vessel walls. Devices according to the invention include an expandable structure arranged around and on a tube having a lumen. The expandable structure may include a sealing ring that makes contact with the interior surface of a vessel to prevent or decrease fluid flow during delivery of a therapeutic agent. This allows delivery of a therapeutic agent with decreased risk of injury to the treatment site. The invention also provides for large lumen diameters, preventing shearing stress on therapeutic agents such as cell slurries.
Owner:BOSTON SCI SCIMED INC
Control Systems and Methods for Blood or Fluid Handling Medical Devices
ActiveUS20160058933A1Prevention and therapyPrevent initiationMechanical/radiation/invasive therapiesOther blood circulation devicesMalwareControl software
A processor of a medical device configured to communicate with a remote server can be programmed to protect the medical device from exposure to unauthorized or malicious software. A system or method to implement this form of protection can include, for example, at least one processor on the medical device, a control software module that controls the operation of the medical device and is executable on the processor, a data management module that manages data flow to and from the control software module from sources external to the medical device, and an agent module that has access to a limited number of designated memory locations in the medical device. In addition, a hemodialysis apparatus can be configured to operate in conjunction with an apparatus for providing purified water from a source such as a municipal water supply or a well. A system for controlling delivery of purified water to the hemodialysis apparatus can comprise a therapy controller of the hemodialysis apparatus configured to communicate with a controller of a water purification device, and a user interface controller of the hemodialysis apparatus configured to communicate with the therapy controller, and to send data to and receive data from a user interface.
Owner:DEKA PROD LLP
Anti-Cd14 Antibody Fusion Protein
InactiveUS20080286290A1Prevention and therapyGuaranteed stable actionAntibacterial agentsBiocideProteinase activityCD14
Owner:MOCHIDA PHARM CO LTD
Chemokine receptor antagonists and use thereof
InactiveUS8168783B2Prevention and therapyBiocideSenses disorderArterial Occlusive DiseasesMental nerve
Owner:ONO PHARMA CO LTD
Gene expression signature for prediction of human cancer progression
InactiveUS20060183141A1Increase probabilityOptimize choiceSugar derivativesMicrobiological testing/measurementHuman cancerLymphatic Spread
Methods are provided for classification of cancers by the expression of a set of genes referred to as the core serum response (CSR), or a subset thereof. The expression pattern of the CSR in normal tissues correlates with that seen in quiescent fibroblasts cultured in the absence of serum, while cancer tissues can be classified as having a quiescent or induced CSR signature. Patients with the induced CSR signature have a higher probability of metastasis. Classification according to CSR signature allows optimization of treatment, and determination of whether on whether to proceed with a specific therapy, and how to optimize dose, choice of treatment, and the like.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Condensed benzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity
To provide a compound having an excellent inhibitory effect on vanilloid receptor subtype 1 (VR1) activity which is effective in treating diseases to which the vanilloid receptor subtype 1 (VR1) activity is involved, such as pain, acute pain, chronic pain, neuropathic pain, rheumatoid arthritis pain, neuralgia, etc. and a pharmaceutical composition containing the compound. The object has been attained by a condensed benzamide compound represented by the following formula (the symbols in the formula have the same meanings defined in the specification) or its salt:
Owner:JAPAN TOBACCO INC
4-Phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (mek) inhibitors
InactiveUS20070105859A1Enhanced inhibitory effectExcellent stability in solubilityAntibacterial agentsBiocideMitogen activate proteinPharmaceutical medicine
Owner:CHUGAI PHARMA CO LTD
Apheresis, administration of agent, or combination thereof
InactiveUS20110033463A1Peripheral side effect be reduceAugment therapyOrganic active ingredientsNervous disorderΓ secretaseAntioxidant
A device is configured to remove a target molecule from a bodily fluid of a subject and to deliver a therapeutic agent to the subject. Such a device may be used for treatment of a disease associated with amyloid beta accumulation in the subject. Agents selected from the group consisting of an ApoE-modulating agent; a RAGE inhibitor; a β-secretase 1 (BACE1) inhibitor; a γ-secretase inhibitor; a muscarinic receptor subtype 1 (M1) agonists; a growth factor; an enzyme capable of degrading amyloid beta; a mitochondrial antioxidant; insulin; and an inhibitor of tumor necrosis factor (TNF) may be administered directly to the central nervous system of a subject for treatment of a disease associated with amyloid beta accumulation.
Owner:MEDTRONIC INC
Compound having acidic group which may be protected, and use thereof
A compound represented by general formula (I):a salt thereof, a solvate thereof, or a prodrug thereof wherein all symbols are as defined in the specification. The compound of the present invention has antagonistic activity against CXCR4 and is therefore useful as a preventive and / or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, systemic erythematosus, retinopathy, macular degeneration, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, cancerous diseases (for example, cancer, cancer metastasis, etc.), or an agent for regeneration therapy.
Owner:ONO PHARMA CO LTD
Novel Anti-Plgf A Antibody
InactiveUS20080193455A1Slow tumor growthInhibit P1GFSenses disorderAntipyreticA AntibodyPathological Angiogenesis
The present invention provides novel monoclonal antibodies directed to P1GF and fragments and derivatives thereof, more particularly to humanized antibodies and fragments thereof for use in the treatment and / or prevention of pathological angiogenesis.
Owner:VLAAMS INTERUNIVERSITAIR INST VOOR BIOTECHNOLOGIE VZW +2
Apheresis of a target molecule from cerebrospinal fluid
InactiveUS20100030196A1Prevention and therapyBlock deliveryWound drainsDialysis systemsAntibodyCatheter device
A system includes (i) a medium having a solid support to which an antibody directed to target molecule is bound, (ii) a reservoir for containing the medium, (iii) a first catheter, and (iv) a second catheter. The first catheter has a proximal end portion, an opening for removal of cerebrospinal fluid from a subject, and a lumen extending from the proximal end portion to the opening. The first catheter is operably couplable to the reservoir such that fluid is capable of flowing from the lumen to the reservoir. The second catheter has a proximal end portion, a delivery region for returning cerebrospinal fluid to the subject, and a lumen extending from the proximal end portion to the delivery region. The second catheter is operably couplable to the reservoir such that fluid is capable of flowing from the reservoir to the lumen.
Owner:MEDTRONIC INC
3-Aminobenzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity
The present invention relates to a novel 3-aminobenzamide compound represented by the following formula which effectively inhibits vanilloid receptor subtype 1 (VR1) activity (wherein, for example, R1 is a C1-6 alkyl group which may be substituted, R2 is a hydrogen atom, a C1-6 alkyl group or a C1-6 alkoxy group which may be substituted, R3 is a hydrogen atom or a C1-6 alkyl group, R4 is a C1-6 alkyl group, a C1-6 alkoxy group, or a halo C1-6 alkyl group, m is an integer of 1 to 5 and P is a carbon or hetero ring) or a pharmaceutically acceptable salt thereof. The pharmaceutical composition comprising as active ingredients the 3-aminobenzamide compound or a pharmaceutically acceptable salt thereof is useful for treating diseases involved in VR1 activity such as pain, acute pain, chronic pain, neuropathic pain, rheumatoid arthritis pain, and neuralgia.
Owner:JAPAN TOBACCO INC
Compound containing basic group and use thereof
The present invention relates to a compound represented by formula (I-0):wherein symbols in formula have the same meanings as described in the present specification, a salt thereof, an N-oxide thereof or a solvate thereof or a prodrug thereof, and medical use thereof. The compound of the present invention has an antagonistic activity against CXCR4 and is therefore useful as a preventive and / or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, retinopathy, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, and cancerous disease (for example, cancer, cancer metastasis, etc.), or an agent for regeneration therapy.
Owner:ONO PHARMA CO LTD
Pyrrolopyridazine derivatives
InactiveUS6063782APrevention and therapyStrong inhibitory activityBiocideOrganic chemistryArylHydrogen atom
Pyrrolopyridazine derivatives having the general formula. In the above formula, R1 represents a C2-C6alkenyl-group, a halogeno-C2-C6-alkenyl group, a C6-C10 aryl-C2-C6-alkenyl group, a C2-C6 alkynyl group, a C3-C7 cycloalkyl group, a C3-C7 cycloalkyl-C1-C6-alkyl group, a C5-C7 cycloalkenyl-C1-C6-alkyl group or a halogeno-C1-C6-alkyl group; R2 and R3 are the same or different and each represents a hydrogen atom, a C1-C6 alkyl group or a C6-C10 aryl group; R4 represents a hydrogen atom or a C1-C6 alkyl group; R5 represents a C6-C10 aryl group or a 5-10 membered heteroaryl group comtaining heteroatom(s) selected from nitrogen, oxygen and sulfur;
Owner:SANKYO CO LTD +1
Hydrazone derivative
A compound represented by the following formula (I): wherein R1 represents hydrogen, aryl which may have a substituent, a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent, etc.; R2 represents hydrogen, aryl which may have a substituent, a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent, etc.; R3 represents hydrogen, etc.; Ar represents a divalent group derived from aromatic hydrocarbon, etc.; X represents a single bond, linear or branched alkylene having from 1 to 3 carbon atoms which may have a substituent, etc.; and G represents halogen, a saturated or unsaturated 5- or 6-membered cyclic hydrocarbon group which may have a substituent, a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent, etc., a salt thereof or a solvate thereof; and an agent for inhibiting aggregation and / or deposition of an amyloid protein or an amyloid-like protein, which comprises the compound, a salt thereof or a solvate thereof.
Owner:DAIICHI PHARMA CO LTD
Compound Containing Basic Group and Use Thereof
InactiveUS20080009495A1Less effectPrevention and therapyBiocideSenses disorderSolventCompound (substance)
The present invention relates to a compound represented by formula (I-0): wherein symbols in formula have the same meanings as described in the present specification, a salt thereof, an N-oxide thereof or a solvate thereof or a prodrug thereof, and medical use thereof. The compound of the present invention has an antagonistic activity against CXCR4 and is therefore useful as a preventive and / or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, retinopathy, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, and cancerous diseases (for example, cancer, cancer metastasis, etc.), or an agent for regeneration therapy.
Owner:ONO PHARMA
Device and method for intra-bronchial provision of a therapeutic agent
InactiveUS20060074382A1Prevent over-inflationPrevention and therapyBronchiTracheaeIntensive care medicineMembrane configuration
Owner:GYRUS ACMI INC (D B A OLYMPUS SURGICAL TECH AMERICA)
3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (VRI) activity
InactiveUS20070149517A1Effective in medical treatmentEffective preventionOrganic active ingredientsNervous disorderDiseaseAlkoxy group
A 3,4-dihydrobenzoxazine compound of the present invention is represented by the following formula [1] (wherein X is a nitrogen atom or CR3; R1 is a hydrogen atom or a halogen atom; R2 is a C1-6 alkoxy group which may be substituted with the same or different 1 to 5 substituents selected from a halogen atom and a hydroxyl group; and R3 is a halogen atom. However, R1 is a halogen atom when X is CR3). This compound is effective in treating diseases to which the vanilloid receptor subtype 1 (VR1) activity is involved, such as pain, etc.
Owner:JAPAN TOBACCO INC
Basic group-containing compound and use thereof
A compound represented by general formula (I):a salt thereof, a solvate thereof, or a prodrug thereof wherein all symbols are as defined in the specification has an antagonistic activity against CXCR4 and is therefore useful as a preventive and / or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, systemic erythematosus, retinopathy, macular degeneration, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiac / vascular disease (for example, arteriosclerosis, myocardial infarction, stenocardia, cerebral infarction, chronic arterial occlusive disease, etc.), metabolic diseases, and cancerous diseases (for example, cancer, cancer metastasis, etc.), a preventive and / or therapeutic agent for cancerous diseases or infections, or an agent for regeneration therapy.
Owner:ONO PHARMA
Substituted polycyclic carbamoylpyridone derivative
This invention provides compounds having antiviral activities especially inhibiting activity for influenza virus, more preferably provides substituted 3-hydroxy-4-pyridone derivatives having cap-dependent endonuclease inhibitory activity.
Owner:SHIONOGI & CO LTD
Anti-CD14 antibody fusion protein
InactiveUS8252905B2Guaranteed stable actionPrevention and therapyAntibacterial agentsBiocideProteinase activityCD14
Owner:MOCHIDA PHARM CO LTD
Therapeutic agent for pruritus
ActiveUS20100310556A1Treating and preventing pruritusPrevention and therapyPeptide/protein ingredientsAntibody ingredientsPrurigoBacteriophage
The present inventors isolated clone BM095 from a human antibody phage library, which had a strong growth inhibitory activity in the IL-31-dependent Ba / F3 cell growth assay system. When administered to pruritus model mice, the anti-mouse NR10 neutralizing antibody exhibited a marked symptom-suppressing effect. Thus, it was revealed that anti-NR10 neutralizing antibodies are useful as therapeutic agents for pruritus.
Owner:CHUGAI PHARMA CO LTD
Compound containing basic group and use thereof
Owner:ONO PHARMA CO LTD
Tricyclic Compound And Use Thereof
ActiveUS20080114012A1Promote oral absorptionHigh affinityBiocideNervous disorderAnti stressMedicinal chemistry
The present invention relates to the compound represented by formula (I):(wherein, all the symbols has the same meanings as that of the specification), a salt thereof, a solvate thereof or a prodrug thereof.Since the compound of the present invention has an anti stress action, it is useful for preventive and / or therapeutic agent for a disease caused by stress, especially a digestive system disease caused by stress and is superior to oral absorption.
Owner:ONO PHARMA CO LTD
Therapeutic composition, and use of a cell-free substance
InactiveUS20100104641A1Efficient preparationHighly efficient mannerBiocidePowder deliveryCell freeMedicine
The invention relates to a therapeutic composition, a method for producing a therapeutic composition, and the use of a cell-free substance, especially a cell-free bone or cartilage matrix. The disclosed therapeutic composition comprises at least a cell-free substance obtained from stimulated stem cells and / or precursor cells. Immunogenic reactions during in vivo therapeutic use are prevented by the fact that the therapeutic composition is free from cells and contains no typically antigenic cell components. The disclosed composition can therefore be universally used for the therapeutic purposes regardless of the origin of the stem cells and / or precursor cells and utilize the natural regenerative potency thereof in a highly efficient manner for replacing tissue, e.g. for a suitable bone and / or cartilage structure.
Owner:STIFTUNG CAESAR +1
17BetaHSD TYPE 5 INHIBITOR
InactiveUS20090181960A1Suppress synthesisSuppress intracrine androgen synthesisBiocideOrganic chemistrySelective inhibitionBenign prostatic hyperplasia (BPH)
To provide a novel and excellent method for treating and / or preventing prostatic cancer, benign prostatic hyperplasia, acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, polycystic ovary syndrome, breast cancer, lung cancer, endometriosis, leiomyoma and the like based on selective inhibitory activity against 17βHSD type 5.It was found that an N-sulfonylindole derivative, where the indole ring is substituted by a carboxy group, a carboxy-substituted lower alkyl group or a carboxy-substituted lower alkenyl group at its carbon atom, has potent selective inhibitory activity against 17βHSD type 5 and may become a therapeutic agent and / or preventive agent for benign prostatic hyperplasia, prostatic cancer and the like without accompanying adverse drug reactions due to a decrease in testosterone, and the present invention has thus been completed.
Owner:ASTELLAS PHARMA INC
Detection of mycobacteria
InactiveUS6383763B1Rapid assessmentLess sensitiveAntibody ingredientsBiological testingMicrobiologyGenus
The present invention is directed to methods and compositions for the detection of infection and disease due to members of the genus Mycobacterium. In particular, the present invention is well-suited to the detection and identification of patients with disease or infection due to M. tuberculosis or MAC.
Owner:CASE WESTERN RESERVE UNIV
Substituted polycyclic pyridone derivatives and prodrugs thereof
ActiveUS20180118760A1Inhibitory activityPrevention and therapyGroup 4/14 element organic compoundsPowder deliveryHalogenHydrogen
The present invention provides the following compounds having anti-viral activity.A1 is CR1AR1B, S or O;A2 is CR2AR2B, S or O;A3 is CR3AR3B, S or O;A4 is CR4AR4B, S or O;the number of hetero atoms among atoms constituting the ring which consists of A1, A2, A3, A4, nitrogen atom adjacent to A1 and carbon atom adjacent to A1, is 1 or 2;R1A and R1B are each independently hydrogen, halogen, alkyl, or the like;R2A and R2B are each independently hydrogen, halogen, alkyl, or the like;R3A and R3B are each independently hydrogen, halogen, alkyl, or the like;R4A and R4B are each independently hydrogen, halogen, alkyl, or the like;R3A and R3B may be taken together to form non-aromatic carbocycle or non-aromatic heterocycle;X is CH2, S or O;R1 is each independently halogen, hydroxy, or the like;m is any integer of 0 to 2; andn is any integer of 1 to 2.
Owner:SHIONOGI & CO LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com